Press Releases

Print Page Print Page        E-mail Page Email Page        RSS Feeds RSS        E-mail Alerts Email Alerts        Financial Tear Sheet Tear Sheet
Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010 | 2009
DateTitle 
12/15/09Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA® in DURATION-5 StudyPrinter Friendly Version
12/08/09Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank Biotech Boston ConfabPrinter Friendly Version
12/03/09Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron PharmaPrinter Friendly Version
11/17/09Alkermes Initiates Phase 2 Clinical Study of ALKS 33 for the Treatment of Alcohol DependencePrinter Friendly Version
11/16/09Alkermes Announces Positive Results from Phase 3 Clinical Study of Naltrexone for Extended-Release Injectable Suspension for the Treatment of Opioid DependencePrinter Friendly Version
11/10/09Alkermes' Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare ConferencePrinter Friendly Version
11/05/09Alkermes Reports Second Quarter Fiscal 2010 Financial ResultsPrinter Friendly Version
11/04/09Alkermes' Corporate Presentation to be Webcast at the Credit Suisse Healthcare ConferencePrinter Friendly Version
10/29/09Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2010Printer Friendly Version
10/27/09Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 37 for the Treatment of Opioid-Induced ConstipationPrinter Friendly Version
10/13/09Alkermes Announces Positive Results From Two Clinical Trials of ALKS 33Printer Friendly Version
09/24/09Alkermes Announces Amylin and Lilly Will Present More than 20 Studies for Exenatide at EASD 2009Printer Friendly Version
09/11/09Alkermes Chairman Richard Pops to Resume Role of CEOPrinter Friendly Version
09/09/09Alkermes' Corporate Presentation to be Webcast at the BioCentury NewsMakers ConferencePrinter Friendly Version
09/08/09Alkermes' Corporate Presentation to be Webcast at the Morgan Stanley Healthcare ConferencePrinter Friendly Version
09/02/09Alkermes' Corporate Presentation to be Webcast at the Thomas Weisel Partners Annual Healthcare ConferencePrinter Friendly Version
08/06/09Alkermes Reports First Quarter Fiscal 2010 Financial ResultsPrinter Friendly Version
07/30/09Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2010Printer Friendly Version
07/29/09Alkermes' Corporate Presentation to be Webcast at the BMO Capital Markets 9th Annual Focus on Healthcare ConferencePrinter Friendly Version
07/20/09Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus(R) in Head-to-Head DURATION-3 StudyPrinter Friendly Version
07/07/09New Drug Application for Exenatide Once Weekly Accepted for Review by FDAPrinter Friendly Version
06/10/09Alkermes' Corporate Presentation to be Webcast at the Jefferies & Company 3rd Annual Healthcare ConferencePrinter Friendly Version
06/07/09Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control with Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009Printer Friendly Version
06/02/09Alkermes' Corporate Presentation to be Webcast at Two Upcoming Investor ConferencesPrinter Friendly Version
05/21/09Alkermes Reports Financial Results for Fiscal 2009 and Provides Financial Expectations for Fiscal 2010Printer Friendly Version
05/19/09RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I DisorderPrinter Friendly Version
05/19/09New Data Demonstrate RISPERDAL® CONSTA® (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia Printer Friendly Version
05/18/09FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I DisorderPrinter Friendly Version
05/14/09Alkermes to Host Conference Call to Discuss Fiscal Year 2009 Financial ResultsPrinter Friendly Version
05/14/09Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank 34th Annual Health Care ConferencePrinter Friendly Version
05/13/09Alkermes Initiates Two New Clinical Trials Of ALKS 33Printer Friendly Version
05/06/09Alkermes' Corporate Presentation to be Webcast at Two Upcoming Investor ConferencesPrinter Friendly Version
05/05/09Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 DiabetesPrinter Friendly Version
04/27/09RISPERDAL(R) CONSTA(R) Approved in JapanPrinter Friendly Version
04/22/09Alkermes Signs Lease for New Headquarters in Waltham, MassachusettsPrinter Friendly Version
04/21/09Alkermes Completes Enrollment for Registration Study of VIVITROL(R) in Patients with Opioid DependencePrinter Friendly Version
04/07/09Alkermes Highlights Advancing Proprietary Product Portfolio at R&D DayPrinter Friendly Version
03/31/09Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 StudyPrinter Friendly Version
03/26/09Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular EventsPrinter Friendly Version
03/24/09Alkermes to Webcast R&D Day on Tuesday, April 7, 2009Printer Friendly Version
03/10/09Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 29th Annual Health Care ConferencePrinter Friendly Version
02/18/09Alkermes Announces Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPDPrinter Friendly Version
02/10/09FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for Adjunctive Maintenance Treatment of Bipolar DisorderPrinter Friendly Version
02/10/09Alkermes' Corporate Presentation to be Webcast at the 21st Annual Roth OC Growth Stock ConferencePrinter Friendly Version
02/05/09Alkermes Announces Third Quarter Fiscal 2009 ResultsPrinter Friendly Version
01/29/09Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2009Printer Friendly Version
01/09/09Alkermes Announces Initiation of First Clinical Study for a Four-Week Long-Acting Injectable Formulation of RisperidonePrinter Friendly Version
01/07/09Alkermes' Corporate Presentation to be Webcast at JPMorgan Annual Healthcare ConferencePrinter Friendly Version